Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- Resource Type
- Article
- Source
- The Lancet; February 2022, Vol. 399 Issue: 10326 p729-740, 12p
- Subject
- Language
- ISSN
- 01406736; 1474547X